Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management
Objectives: To review the current definitions and diagnostic criteria for acute kidney injury (AKI) and type 1 hepatorenal syndrome (HRS) now termed HRS-AKI and discuss the challenges in deciding the most appropriate medication regimens to treat patients with HRS-AKI. Data sources: PubMed (inception...
Gespeichert in:
| Veröffentlicht in: | Annals of Pharmacotherapy 2024-02, Vol.58 (2), p.156-164 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 164 |
|---|---|
| container_issue | 2 |
| container_start_page | 156 |
| container_title | Annals of Pharmacotherapy |
| container_volume | 58 |
| creator | Erstad, Brian L. |
| description | Objectives:
To review the current definitions and diagnostic criteria for acute kidney injury (AKI) and type 1 hepatorenal syndrome (HRS) now termed HRS-AKI and discuss the challenges in deciding the most appropriate medication regimens to treat patients with HRS-AKI.
Data sources:
PubMed (inception to April 2023) with bibliographies of retrieved articles searched for additional articles; organizational websites for clinical practice guidelines (CPGs).
Study selection and data extraction:
Randomized controlled trials (RCTs) evaluating albumin and vasoconstrictors for HRS-AKI.
Data synthesis:
A major change in the most recent revision of definitions and diagnostic criteria for HRS-AKI is the elimination of the set cutoff serum creatinine values for AKI. This change should be considered when comparing studies of HRS-AKI over time. Albumin has been administered to both vasoconstrictor treatment and placebo groups in all recent RCTs; however, there has never been a large RCT evaluating a no-albumin group. Most prospective trials comparing a midodrine/octreotide combination or norepinephrine to placebo or terlipressin have enrolled less than 100 patients limiting any conclusions regarding clinically important outcomes. Terlipressin with albumin has shown mixed results for complete HRS-AKI reversal with no reductions in crude mortality but adverse effect concerns involving ischemic and pulmonary events.
Relevance to patient care and clinical practice:
Type 1 hepatorenal syndrome with acute kidney injury is a potentially life-threatening syndrome with diagnostic and treatment challenges. Albumin plus a vasoconstrictor has become the routine HRS-AKI treatment even though there has not been a large RCT evaluating a no-albumin group. Terlipressin is the vasoconstrictor of choice for HRS-AKI in current CPGs, but it has adverse effect concerns and, until recently, was not available in the United States.
Conclusions:
In conjunction with changes in the definitions and diagnostic criteria for HRS-AKI, debate continues regarding the optimal therapy for HRS-AKI, particularly considering recent trials demonstrating ischemic and pulmonary adverse events with terlipressin used in combination with albumin. |
| doi_str_mv | 10.1177/10600280231177698 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2822706483</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10600280231177698</sage_id><sourcerecordid>2822706483</sourcerecordid><originalsourceid>FETCH-LOGICAL-c292t-1f45312db9e69a13c1de9aa02aa361e92197da16aa4997935177722274fe92103</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EoqXwAViQR5YU20ntmK0qf1rRqgMgxuiaXEqqxCl2MuTb46iFBYnp7nS_96T3CLnmbMy5UnecScZEzETYn1LHJ2TIJ5EIpFDs1O_-H_TAgFw4t2OMaS70ORmESiiupRqS9Rz30NQWDZT0tTOZrSukH0XzSadp2yB9KTKDHV2YXWu7e_pQwNbUrnAUTEZXmBWpF67AwBYrNM0lOcuhdHh1nCPy_vT4NpsHy_XzYjZdBqnQogl4Hk1CLrKNRqmBhynPUAMwARBKjlpwrTLgEiDSWulw4vMpIYSK8v7JwhG5Pfjubf3VomuSqnApliUYrFuXiNjDTEZx6FF-QFNbO2cxT_a2qMB2CWdJX1zyp0evuTnat5sKs1_FT3EeGB8A54Mnu7q1vkD3j-M3L1V4pQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2822706483</pqid></control><display><type>article</type><title>Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management</title><source>MEDLINE</source><source>SAGE Journals</source><creator>Erstad, Brian L.</creator><creatorcontrib>Erstad, Brian L.</creatorcontrib><description>Objectives:
To review the current definitions and diagnostic criteria for acute kidney injury (AKI) and type 1 hepatorenal syndrome (HRS) now termed HRS-AKI and discuss the challenges in deciding the most appropriate medication regimens to treat patients with HRS-AKI.
Data sources:
PubMed (inception to April 2023) with bibliographies of retrieved articles searched for additional articles; organizational websites for clinical practice guidelines (CPGs).
Study selection and data extraction:
Randomized controlled trials (RCTs) evaluating albumin and vasoconstrictors for HRS-AKI.
Data synthesis:
A major change in the most recent revision of definitions and diagnostic criteria for HRS-AKI is the elimination of the set cutoff serum creatinine values for AKI. This change should be considered when comparing studies of HRS-AKI over time. Albumin has been administered to both vasoconstrictor treatment and placebo groups in all recent RCTs; however, there has never been a large RCT evaluating a no-albumin group. Most prospective trials comparing a midodrine/octreotide combination or norepinephrine to placebo or terlipressin have enrolled less than 100 patients limiting any conclusions regarding clinically important outcomes. Terlipressin with albumin has shown mixed results for complete HRS-AKI reversal with no reductions in crude mortality but adverse effect concerns involving ischemic and pulmonary events.
Relevance to patient care and clinical practice:
Type 1 hepatorenal syndrome with acute kidney injury is a potentially life-threatening syndrome with diagnostic and treatment challenges. Albumin plus a vasoconstrictor has become the routine HRS-AKI treatment even though there has not been a large RCT evaluating a no-albumin group. Terlipressin is the vasoconstrictor of choice for HRS-AKI in current CPGs, but it has adverse effect concerns and, until recently, was not available in the United States.
Conclusions:
In conjunction with changes in the definitions and diagnostic criteria for HRS-AKI, debate continues regarding the optimal therapy for HRS-AKI, particularly considering recent trials demonstrating ischemic and pulmonary adverse events with terlipressin used in combination with albumin.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1177/10600280231177698</identifier><identifier>PMID: 37271967</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Acute Kidney Injury - chemically induced ; Acute Kidney Injury - diagnosis ; Acute Kidney Injury - therapy ; Albumins - therapeutic use ; Hepatorenal Syndrome - diagnosis ; Hepatorenal Syndrome - drug therapy ; Humans ; Terlipressin - therapeutic use ; Treatment Outcome ; Vasoconstrictor Agents</subject><ispartof>Annals of Pharmacotherapy, 2024-02, Vol.58 (2), p.156-164</ispartof><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c292t-1f45312db9e69a13c1de9aa02aa361e92197da16aa4997935177722274fe92103</cites><orcidid>0000-0001-8909-9921</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/10600280231177698$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/10600280231177698$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>313,314,780,784,792,21819,27922,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37271967$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Erstad, Brian L.</creatorcontrib><title>Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management</title><title>Annals of Pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>Objectives:
To review the current definitions and diagnostic criteria for acute kidney injury (AKI) and type 1 hepatorenal syndrome (HRS) now termed HRS-AKI and discuss the challenges in deciding the most appropriate medication regimens to treat patients with HRS-AKI.
Data sources:
PubMed (inception to April 2023) with bibliographies of retrieved articles searched for additional articles; organizational websites for clinical practice guidelines (CPGs).
Study selection and data extraction:
Randomized controlled trials (RCTs) evaluating albumin and vasoconstrictors for HRS-AKI.
Data synthesis:
A major change in the most recent revision of definitions and diagnostic criteria for HRS-AKI is the elimination of the set cutoff serum creatinine values for AKI. This change should be considered when comparing studies of HRS-AKI over time. Albumin has been administered to both vasoconstrictor treatment and placebo groups in all recent RCTs; however, there has never been a large RCT evaluating a no-albumin group. Most prospective trials comparing a midodrine/octreotide combination or norepinephrine to placebo or terlipressin have enrolled less than 100 patients limiting any conclusions regarding clinically important outcomes. Terlipressin with albumin has shown mixed results for complete HRS-AKI reversal with no reductions in crude mortality but adverse effect concerns involving ischemic and pulmonary events.
Relevance to patient care and clinical practice:
Type 1 hepatorenal syndrome with acute kidney injury is a potentially life-threatening syndrome with diagnostic and treatment challenges. Albumin plus a vasoconstrictor has become the routine HRS-AKI treatment even though there has not been a large RCT evaluating a no-albumin group. Terlipressin is the vasoconstrictor of choice for HRS-AKI in current CPGs, but it has adverse effect concerns and, until recently, was not available in the United States.
Conclusions:
In conjunction with changes in the definitions and diagnostic criteria for HRS-AKI, debate continues regarding the optimal therapy for HRS-AKI, particularly considering recent trials demonstrating ischemic and pulmonary adverse events with terlipressin used in combination with albumin.</description><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - diagnosis</subject><subject>Acute Kidney Injury - therapy</subject><subject>Albumins - therapeutic use</subject><subject>Hepatorenal Syndrome - diagnosis</subject><subject>Hepatorenal Syndrome - drug therapy</subject><subject>Humans</subject><subject>Terlipressin - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Vasoconstrictor Agents</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD9PwzAQxS0EoqXwAViQR5YU20ntmK0qf1rRqgMgxuiaXEqqxCl2MuTb46iFBYnp7nS_96T3CLnmbMy5UnecScZEzETYn1LHJ2TIJ5EIpFDs1O_-H_TAgFw4t2OMaS70ORmESiiupRqS9Rz30NQWDZT0tTOZrSukH0XzSadp2yB9KTKDHV2YXWu7e_pQwNbUrnAUTEZXmBWpF67AwBYrNM0lOcuhdHh1nCPy_vT4NpsHy_XzYjZdBqnQogl4Hk1CLrKNRqmBhynPUAMwARBKjlpwrTLgEiDSWulw4vMpIYSK8v7JwhG5Pfjubf3VomuSqnApliUYrFuXiNjDTEZx6FF-QFNbO2cxT_a2qMB2CWdJX1zyp0evuTnat5sKs1_FT3EeGB8A54Mnu7q1vkD3j-M3L1V4pQ</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Erstad, Brian L.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8909-9921</orcidid></search><sort><creationdate>202402</creationdate><title>Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management</title><author>Erstad, Brian L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c292t-1f45312db9e69a13c1de9aa02aa361e92197da16aa4997935177722274fe92103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - diagnosis</topic><topic>Acute Kidney Injury - therapy</topic><topic>Albumins - therapeutic use</topic><topic>Hepatorenal Syndrome - diagnosis</topic><topic>Hepatorenal Syndrome - drug therapy</topic><topic>Humans</topic><topic>Terlipressin - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Vasoconstrictor Agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erstad, Brian L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erstad, Brian L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management</atitle><jtitle>Annals of Pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2024-02</date><risdate>2024</risdate><volume>58</volume><issue>2</issue><spage>156</spage><epage>164</epage><pages>156-164</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><abstract>Objectives:
To review the current definitions and diagnostic criteria for acute kidney injury (AKI) and type 1 hepatorenal syndrome (HRS) now termed HRS-AKI and discuss the challenges in deciding the most appropriate medication regimens to treat patients with HRS-AKI.
Data sources:
PubMed (inception to April 2023) with bibliographies of retrieved articles searched for additional articles; organizational websites for clinical practice guidelines (CPGs).
Study selection and data extraction:
Randomized controlled trials (RCTs) evaluating albumin and vasoconstrictors for HRS-AKI.
Data synthesis:
A major change in the most recent revision of definitions and diagnostic criteria for HRS-AKI is the elimination of the set cutoff serum creatinine values for AKI. This change should be considered when comparing studies of HRS-AKI over time. Albumin has been administered to both vasoconstrictor treatment and placebo groups in all recent RCTs; however, there has never been a large RCT evaluating a no-albumin group. Most prospective trials comparing a midodrine/octreotide combination or norepinephrine to placebo or terlipressin have enrolled less than 100 patients limiting any conclusions regarding clinically important outcomes. Terlipressin with albumin has shown mixed results for complete HRS-AKI reversal with no reductions in crude mortality but adverse effect concerns involving ischemic and pulmonary events.
Relevance to patient care and clinical practice:
Type 1 hepatorenal syndrome with acute kidney injury is a potentially life-threatening syndrome with diagnostic and treatment challenges. Albumin plus a vasoconstrictor has become the routine HRS-AKI treatment even though there has not been a large RCT evaluating a no-albumin group. Terlipressin is the vasoconstrictor of choice for HRS-AKI in current CPGs, but it has adverse effect concerns and, until recently, was not available in the United States.
Conclusions:
In conjunction with changes in the definitions and diagnostic criteria for HRS-AKI, debate continues regarding the optimal therapy for HRS-AKI, particularly considering recent trials demonstrating ischemic and pulmonary adverse events with terlipressin used in combination with albumin.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>37271967</pmid><doi>10.1177/10600280231177698</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-8909-9921</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1060-0280 |
| ispartof | Annals of Pharmacotherapy, 2024-02, Vol.58 (2), p.156-164 |
| issn | 1060-0280 1542-6270 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2822706483 |
| source | MEDLINE; SAGE Journals |
| subjects | Acute Kidney Injury - chemically induced Acute Kidney Injury - diagnosis Acute Kidney Injury - therapy Albumins - therapeutic use Hepatorenal Syndrome - diagnosis Hepatorenal Syndrome - drug therapy Humans Terlipressin - therapeutic use Treatment Outcome Vasoconstrictor Agents |
| title | Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A18%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatorenal%20Syndrome%20With%20Acute%20Kidney%20Injury:%20Diagnosis%20and%20Medical%20Management&rft.jtitle=Annals%20of%20Pharmacotherapy&rft.au=Erstad,%20Brian%20L.&rft.date=2024-02&rft.volume=58&rft.issue=2&rft.spage=156&rft.epage=164&rft.pages=156-164&rft.issn=1060-0280&rft.eissn=1542-6270&rft_id=info:doi/10.1177/10600280231177698&rft_dat=%3Cproquest_cross%3E2822706483%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2822706483&rft_id=info:pmid/37271967&rft_sage_id=10.1177_10600280231177698&rfr_iscdi=true |